CPT 84112 is referenced in 8 tracked payer policy changes from BCBS Arizona, CareSource, and 3 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 84112 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield of Arizona has issued a new Evidence-Based Criteria policy (effective 11/01/26) that classifies 62 specific CPT and HCPCS codes as experimental or investigational services and therefore non-covered. This policy applies broadly across multiple specialties and requires billing teams to deny claims for these codes unless members have explicit coverage for experimental services in their benefit plans.
CareSource Georgia Medicaid is implementing new prior authorization requirements effective April 1, 2026, for 57 specific billing codes across multiple service categories including genetic testing, durable medical equipment, orthotic/prosthetic devices, and surgical procedures. All non-participating providers and inpatient services already require prior auth; this update expands requirements to include these specific codes for all providers.
Blue Shield of California's Investigational Services policy (BSC9.01) has an effective date of 09/01/2026. It defines healthcare services as investigational when all three apply: testing is not complete, the efficacy and safety of the service in human subjects are not yet established, and the service is not in wide usage. The policy addresses services that are not covered because they are considered investigational, and its code table lists CPT codes from 22526 through 1025T, many of them effective 1/1/2026.
Sentara Health Plans' authorization updates took effect August 1, 2025, and on that date several Commercial and Medicaid policies were archived, including brachytherapy and proton beam radiation therapy. Prior authorization was removed for codes 61781, 61782 and 61783 (Commercial and Medicaid), 84112, 98975, 98976, 98977, 98978, 98980 and 98981 (Commercial, Medicaid and Medicare), 99473 and 99474 (Medicare), 0091U, 86152 and 86153 (Commercial, Medicaid and Medicare), and S9110 (Medicaid). Separate authorization updates took effect January 1, 2025 and July 1, 2025, and authorization is required with hour limits for a group of psychological and neuropsychological testing codes for Commercial plans as of August 1, 2025.
Sentara Health Plans notified providers of summer 2025 authorization updates with go-live dates of July 1, 2025, August 1, 2025 and October 1, 2025. Many policies had criteria updated for Commercial and Medicaid, while Medicare continued to use the LCD and NCD policies listed for each service. Several policies were archived, and prior authorization was removed for codes including 61781, 61782 and 61783 for Commercial and Medicaid.
Aetna considers the non-invasive fetal membranes rupture tests, including Actim PROM, AmniSure ROM, Chorioquick and the ROM Plus Fetal Membranes Rupture Test, experimental, investigational, or unproven for detecting preterm rupture of membranes and for all other indications. Aetna also considers the Biobeat Monitoring Platform, evaluation of vaginal microbiome profiles, fetal membrane imaging, functional placental MRI and amniotic fluid suPAR experimental, investigational, or unproven for their listed uses. CPT codes 84112, 74712 and 74713 are not covered for the indications listed.
Aetna's Clinical Policy Bulletin 0757 considers non-invasive fetal membranes rupture tests, including Actim PROM, AmniSure ROM, Chorioquick and the ROM Plus Fetal Membranes Rupture Test, experimental, investigational or unproven for detecting preterm rupture of membranes and all other indications. The same status applies to the Biobeat Monitoring Platform, evaluation of vaginal microbiome profiles, fetal membrane imaging, functional placental MRI for infection or inflammation in preterm PROM, and amniotic fluid suPAR for diagnosing fetal inflammatory response syndrome. The policy also lists specific CPT codes, including 84112 for cervicovaginal fluid amniotic protein evaluation, as not covered for the indications it lists.
Aetna considers the fetal fibronectin (fFN) immunoassay medically necessary to evaluate pregnant women with symptoms of preterm labor who are considered high-risk for preterm delivery when amniotic membranes are intact, cervical dilation is less than 3 cm, sampling occurs no earlier than 24 weeks 0 days and no later than 34 weeks 6 days of gestation, and results will be available quickly enough to influence real-time decisions for suspected preterm labor. A repeat fFN immunoassay is medically necessary when the member meets all of the same criteria and remains symptomatic 2 or more weeks after a previous negative fFN immunoassay. Fetal fibronectin testing for routine screening of the general obstetric population, for asymptomatic high-risk women, for identifying optimal cerclage candidates, and following cervical cerclage insertion is experimental, investigational or unproven, as are the biomarker, inflammatory marker, proteomic, metabolomic and salivary hormone tests named for preterm birth prediction.
Watch 84112
Get one email when a payer policy names 84112, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for 84112
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 84112 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.